Home
About
Services
Partners
Client Portfolio
News
Contact
China’s caffeine war: Fast-growing Luckin brews up a threat to Starbucks
July 24, 2018
Stock futures rise as Alphabet gains, lifts FAANG stocks
July 24, 2018
0
Biogen beats estimates on Spinraza sales, raises forecast
Published by
Muller&Green
at
July 24, 2018
Categories
RSS
Tags
Biogen Inc reported a better-than-expected quarterly profit on Tuesday and raised its forecast for 2018 adjusted earnings, driven by strong demand for its spinal muscular atrophy drug Spinraza, sending its shares up 3 percent.
Powered by
WPeMatico
Muller&Green
Related posts
June 18, 2020
Chanel warns virus impact will linger on luxury sector
Read more
June 18, 2020
IMF says deeper-than-expected contraction in U.S. economy likely in second quarter
Read more
June 18, 2020
Prudential sells Jackson equity stake to Apollo-backed Athene for $500 million
Read more